A Phase 2 interventional study of Atazanavir (ATV) 300 mg and Atazanavir (ATV) 400 mg in HIV Infections and Acquired Immunodeficiency Syndrome, sponsored by Janssen R&D Ireland. Completed at 19 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-09-30.
Sponsored by Janssen R&D Ireland · Phase 2, Interventional, and Treatment
The purpose of this study is to determine the pharmacokinetics (how the body absorbs, distributes, metabolizes and eliminates a drug) (PK) of ETR when given with ATV/rtv and 1 NRTI in treatment experienced HIV-1 infected patients. In addition, safety, tolerability and anti-HIV effect of this regimen will also be studied. A total of 46 patients will be enrolled.
This is a randomized (study drug assigned by chance), exploratory, open-label (all involved people know the identity of the intervention) trial to evaluate the pharmacokinetics (PK), safety, tolerability and anti-HIV (anti Human Immunodeficiency Virus) activity of etravirine (ETR ) when given with atazanavir/ritonavir (ATV/rtv) and 1 nucleoside reverse transcriptase inhibitor (NRTI) in 46 treatment experienced HIV-1 infected patients. The trial will consist of : 4 weeks of Screening Period, 2 weeks Pre-Treatment Phase, 48-week Treatment Period, and a Final Visit followed by a 4-week Follow-up Period (only for patients not continuing treatment with ETR in another trial or program). Safety evaluations (AE reporting, labs, vital signs, etc.) will be monitored at each study visit. A PK substudy (included in the protocol, with optional participation) with tenofovir (TDF) added to the antiretroviral regimen for 7 days will be conducted in patients with > 24 weeks of treatment with suppressed HIV-1 viral load. In Pre-Treatment Phase, all patients will receive ATV/rtv 300/100 mg once daily to be taken following a meal each morning + 2 NRTIs (dose as specified in the labels) for 14 days. In Treatment Phase, patients will receive ETR 200 mg twice daily in addition to ATV/rtv (300/100 mg or 400/100 mg) once daily with meals + 1 investigator-selected NRTI for 48 weeks. In substudy TDF 300 mg once daily will be added to the treatment regimen x 7 days.
4,258 studies on the registry are indexed under HIV Infections; 240 are open to participants now.
This study's enrollment of 50 is below the median of 83 across 3,251 interventional studies indexed under HIV Infections.
Browse HIV Infections studies →Janssen R&D Ireland is the lead sponsor of 31 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Grade 3 or 4 toxicities (according to DAIDS grading)
Treatment-experienced human immunodeficiency virus - type 1 (HIV-1) infected participants will take by mouth atazanavir (ATV)/low-dose ritonavir (rtv) 300/100 mg once daily + 2 nucleoside reverse transcriptase inhibitors (NRTIs) for 2 weeks pre-treatment followed by ATV/rtv 300/100 mg once daily + etravirine (ETR) 200 mg twice daily + 1 NRTI for 48 weeks. If particpating in an optional substudy to assess the effect of adding tenofovir disoproxil fumarate (TDF) for 7 days on ATV and ETR pharmacokinetics, participants will receive TDF 300 mg once daily for 7 days in addition to their antiretroviral regimen (ETR+ATV/rtv+NRTI).
Drug: Atazanavir (ATV) 300 mg · Drug: Ritonavir (rtv) 100 mg · Drug: Nucleo(side)/(tide) reverse transcriptase inhibitors (NRTIs) · Drug: Etravirine (ETR) 200 mg · Drug: Tenofovir disoproxil fumarate (TDF) 300 mg
Treatment-experienced human immunodeficiency virus - type 1 (HIV-1) infected participants will take by mouth atazanavir (ATV)/low-dose ritonavir (rtv) 300/100 mg once daily + 2 nucleoside reverse transcriptase inhibitors (NRTIs) for 2 weeks pretreatment followed by ATV/rtv 400/100 mg once daily + etravirine (ETR) 200 mg twice daily + 1 NRTI for 48 weeks. If particpating in an optional substudy to assess the effect of adding tenofovir disoproxil fumarate (TDF) for 7 days on ATV and ETR pharmacokinetics, participants will take TDF 300 mg once daily for 7 days in addition to their antiretroviral regimen (ETR+ATV/rtv+NRTI).
Drug: Atazanavir (ATV) 400 mg · Drug: Ritonavir (rtv) 100 mg · Drug: Nucleo(side)/(tide) reverse transcriptase inhibitors (NRTIs) · Drug: Etravirine (ETR) 200 mg · Drug: Tenofovir disoproxil fumarate (TDF) 300 mg
Atazanavir (ATV) 300 mg taken by mouth following a meal each morning for 2 weeks during the Pre-Treatment Period and for 48 weeks during the Treatment Period. If participating in the optional substudy, participants will take ATV 300 mg by mouth following a meal each morning on Substudy Days -1 to 7.
Atazanavir (ATV) 400 mg taken by mouth following a meal each morning for 2 weeks during the Pre-Treatment Period and for 48 weeks during the Treatment Period. If participating in the optional substudy, participants will take ATV 400 mg by mouth following a meal each morning on Substudy Days -1 to 7.
Ritonavir (rtv) 100 mg taken by mouth following a meal each morning for 2 weeks during the Pre-Treatment Period and for 48 weeks during the Treatment Period. If participating in the optional substudy, participants will take rtv 100 mg by mouth following a meal each morning on Substudy Days -1 to 7.
2 investigator-selected NRTIs taken as specified in the individual product labels for 2 weeks during the Pre-Treatment Period followed by 1 investigator-selected NRTI (of the 2 NRTIs in the Pre-Treatment Phase) taken as specified in the individual product label for 48 weeks during the Treatment Period. If participating in the optional substudy, participants will take 1 investigator-selected NRTI (of the 2 NRTIs in the Pre-Treatment Phase) mg taken as specified in the individual product label during the Substudy.
Etravirine (ETR) 200 mg taken twice daily as two 100-mg tablets following a meal (morning and evening) for at least the first two weeks of the 48-week Treatment Period. If participating in the optional substudy, participants will take ETR 200 mg twice daily as two 100-mg tablets following a meal each morning and evening on Substudy Days -1 to 7.
Tenofovir disoproxil fumarate (TDF) 300 mg taken by mouth following a meal each morning on Substudy Days 1 to 7.
Pharmacokinetic Results of Atazanavir (ATV): Treatment A: ATV/Low-Dose Ritonavir (Rtv) 300/100 mg (Results for C0h, Cmin, and Cmax)
The table below shows pharmacokinetic (PK) results of atazanavir (ATZ) when administered as ATV/rtv 300/100 mg pretreatment (Reference) and at Week 2 after treatment (Test). Results are expressed as the predose plasma concentration (C0h), minimum plasma concentration (Cmin), and maximum plasma concentration (Cmax).
Time frame: Day -1 (Pretreatment); Week 2 (Test)
Pharmacokinetic Results of Atazanavir (ATV): Treatment A: ATV/Low-Dose Ritonavir (Rtv) 300/100 mg (Results for AUC24hr)
The table below shows pharmacokinetic (PK) results of atazanavir (ATZ) when administered as ATV/rtv 300/100 mg pretreatment (Reference) and at Week 2 after treatment (Test). Results are expressed as the area under the plasma concentration-time curve from time of intake to 24 hours after dosing (AUC24hr).
Time frame: Day -1 (Pretreatment); Week 2 (Test)
Pharmacokinetic Results of Atazanavir (ATV): Treatment B: ATV/Low-Dose Ritonavir (Rtv) 400/100 mg (Results for C0h, Cmin, and Cmax)
The table below shows pharmacokinetic (PK) results of atazanavir (ATV) when administered as ATV/ritonavir (rtv) 300/100 mg pretreatment (Reference) and when administered as ATV/rtv 400/100 mg at Week 2 after treatment (Test). Results are expressed as the predose plasma concentration (C0h), minimum plasma concentration (Cmin), maximum plasma concentration (Cmax), and area under the plasma concentration-time curve from time of intake to 24 hours after dosing (AUC24hr).
Time frame: Day -1 (Reference); Week 2 (Test)
Pharmacokinetic Results of Atazanavir (ATV): Treatment B: ATV/Low-Dose Ritonavir (Rtv) 400/100 mg (Results for AUC24hr)
The table below shows pharmacokinetic (PK) results of atazanavir (ATV) when administered as ATV/ritonavir (rtv) 300/100 mg pretreatment (Reference) and when administered as ATV/rtv 400/100 mg at Week 2 after treatment (Test). Results are expressed as the area under the plasma concentration-time curve from time of intake to 24 hours after dosing (AUC24hr).
Time frame: Day -1 (Reference); Week 2 (Test)
Pharmacokinetic Results of Low-Dose Ritonavir (Rtv): Treatment A: Atazanavir (ATV)/Rtv 300/100 mg (Results for C0h, Cmin, and Cmax)
The table below shows the pharmacokinetic (PK) results of low-dose ritonavir (rtv) when administered as atazanavir (ATV)/rtv 300/100 mg pretreatment (Reference) and at Week 2 after treatment (Test). Results are expressed as the predose plasma concentration (C0h), minimum plasma concentration (Cmin), and maximum plasma concentration (Cmax).
Time frame: Day -1 (Reference); Week 2 (Test)
Pharmacokinetic Results of Low-Dose Ritonavir (Rtv): Treatment A: Atazanavir (ATV)/Rtv 300/100 mg (Results for AUC24hr)
The table below shows the pharmacokinetic (PK) results of low-dose ritonavir (rtv) when administered as atazanavir (ATV)/rtv 300/100 mg pretreatment (Reference) and at Week 2 after treatment (Test). Results are expressed as the area under the plasma concentration-time curve from time of intake to 24 hours after dosing (AUC24hr).
Time frame: Day -1 (Reference); Week 2 (Test)
Pharmacokinetic Results of Low-Dose Ritonavir (Rtv): Treatment B: Atazanavir (ATV)/Rtv 400/100 mg (Results for C0h, Cmin, and Cmax)
The table below shows pharmacokinetic (PK) results of low-dose ritonavir (rtv) when administered as atazanavir (ATV)/ritonavir (rtv) 300/100 mg pretreatment (Reference) and when administered as ATV/rtv 400/100 mg at Week 2 after treatment (Test). Results are expressed as the predose plasma concentration (C0h), minimum plasma concentration (Cmin), maximum plasma concentration (Cmax), and area under the plasma concentration-time curve from time of intake to 24 hours after dosing (AUC24hr).
Time frame: Day -1 (Reference); Week 2 (Test)
Pharmacokinetic Results of Low-Dose Ritonavir (Rtv): Treatment B: Atazanavir (ATV)/Rtv 400/100 mg (Results for AUC24hr)
The table below shows pharmacokinetic (PK) results of low-dose ritonavir (rtv) when administered as atazanavir (ATV)/ritonavir (rtv) 300/100 mg pretreatment (Reference) and when administered as ATV/rtv 400/100 mg at Week 2 after treatment (Test). Results are expressed as the area under the plasma concentration-time curve from time of intake to 24 hours after dosing (AUC24hr).
Time frame: Day -1 (Reference); Week 2 (Test)
Pharmacokinetic Results of Etravirine (ETR) (Results for C0h, Cmin, and Cmax)
The table below shows pharmacokinetic (PK) results of ETR in the current study expressed as the predose plasma concentration (C0h), minimum plasma concentration (Cmin) and maximum plasma concentration (Cmax).
Time frame: Week 2
Pharmacokinetic Results of Etravirine (ETR) (Results for AUC12hr)
The table below shows pharmacokinetic (PK) results of ETR in the current study expressed as the area under the plasma concentration-time curve from time of intake to 12 hours after dosing (AUC12hr).
Time frame: Week 2
Percentage of Participants With Undetectable Plasma Viral Load (VL) Values (<50 Copies/mL) at Week 48
The table below shows the percentage of participants wih undetectable plasma viral load (VL) values (\<50 copies/mL) at Week 48 using the Non-Completing = Failure (NC=F) imputation method (ie, participants who discontinued early were counted as nonresponders by having their VL values after discontinuation imputed with their baseline value, thus resulting in a 0 change).
Time frame: Week 48
Change From Prebaseline in CD4+ Cell Count Over Time
The table below shows the mean change from prebaseline over time in CD4+ cell count using the Non-Completing = Failure (NC=F) imputation method.
Time frame: Prebaseline, Baseline, Weeks 4, 12, 24, 48
The Percentage of Participants With a Virologic Response Using the Non-Completing = Failure (NC=F) Imputation Method
The table below shows the percentage of participants per time point with a virologic response defined as having a plasma viral load (VL) \<50 copies/mL, and with plasma VL \<400 copies/mL using the Non-Completing = Failure (NC=F) imputation method (ie, participants who discontinued early were counted as nonresponders by having their VL values after discontinuation imputed with their Baseline value, thus resulting in a 0 change).
Time frame: Baseline, Weeks 4, 12, 24, 48
The Percentage of Participants With a Virologic Response Using the Time to Loss of Virologic Response (TLOVR) Imputation Method
The table below shows the percentage of participants with a virologic response defined as a viral load \<50 Copies/mL and \<400 Copies/mL per time point calculated using the time to loss of virologic response (TLOVR) imputation method.
Time frame: Baseline, Weeks 4, 12, 24, 48
The Percentage of Participants With a Virologic Response (Plasma Viral Load < 50 Copies/mL) at Week 48 Using the Snapshot Analysis Method
The table below provides the results from the snapshot analysis method that includes the percentage of participants with virologic response (\<50 copies/mL), the percentage of participants who were virologic failures (VF) (\>50 copies/mL, discontinued prior to time X for reasons of VF or for other reasons, except for VF or adverse event, with a last viral load \>50 copies/mL), and the percentage of participants with no viral load (VL) data available at Week 48.
Time frame: Week 48
Change From Pre-Baseline in Log10 Viral Load Over Time
The table below shows the mean change from prebaseline over time in log10 (Copies/mL) plasma viral load using the Non-Completing = Failure (NC=F) imputation method.
Time frame: Pre-Baseline, Baseline, Weeks 4, 12, 24, 48
Time to Confirmed Virologic Response
The table below provides the time in days it took participants to reach a confirmed virologic response defined as a plasma viral load (VL) \<50 copies/mL, and plasma VL \<400 copies/mL analyzed according to the Time to Loss of Virologic Response (TLOVR) imputation method.
Time frame: Prebaseline to Week 48
Time to Virologic Failure
The table below shows the number of days to virologic failure defined as a plasma viral load (VL) \> 50 copies/mL for participants who had been virologic responders (ie, having a plasma VL \<50, and \<400 copies/mL according to the time to loss of virologic response \[TLOVR\] imputation method). Time to virologic failure was the time to subsequent loss of virologic response, and the time was calculated from Prebaseline (Week -2). Participants who never achieved a virologic response were defined as nonresponders and counted as virologic failures on Day 1.
Time frame: Prebaseline to Week 48
Etravirine coadministered with 2 doses of atazanavir/low-dose ritonavir each combined with 1 nucleoside reverse transcriptase inhibitor was evaluated in human immunodeficiency virus - type 1 infected participants. The study was conducted between 25 June 2009 and 10 April 2012 and participants were recruited by 17 investigators in 4 countries.
| Milestone | ATV/Rtv 300/100 mg (Treatment A) | ATV/Rtv 400/100 mg (Treatment B) |
|---|---|---|
| Started | 25 | 25 |
| Completed | 15 | 16 |
| Not completed | 10 | 9 |
| Withdrew: Adverse event | 2 | 1 |
| Withdrew: Lost to follow-up | 3 | 2 |
| Withdrew: Withdrawal by subject | 3 | 2 |
| Withdrew: Subject noncompliant | 1 | 3 |
| Withdrew: Other | 1 | 1 |
The table below shows pharmacokinetic (PK) results of atazanavir (ATZ) when administered as ATV/rtv 300/100 mg pretreatment (Reference) and at Week 2 after treatment (Test). Results are expressed as the predose plasma concentration (C0h), minimum plasma concentration (Cmin), and maximum plasma concentration (Cmax).
| ng/ml | ATV/Rtv 300/100 mg (Reference) | ATV/Rtv 300/100 mg (Test) |
|---|---|---|
| C0h, ng/ml (Reference, n=21; Test, n=19) | 1339 ± 1728 | 845.7 ± 703.3 |
| Cmin, ng/ml (Reference, n=20; Test, n=18) | 1104 ± 1511 | 758.6 ± 610.5 |
| Cmax, ng/ml (Reference, n=20; Test, n=19) | 5652 ± 2735 | 5232 ± 2166 |
The table below shows pharmacokinetic (PK) results of atazanavir (ATZ) when administered as ATV/rtv 300/100 mg pretreatment (Reference) and at Week 2 after treatment (Test). Results are expressed as the area under the plasma concentration-time curve from time of intake to 24 hours after dosing (AUC24hr).
| ng.h/mL | ATV/Rtv 300/100 mg (Reference) | ATV/Rtv 300/100 mg (Test) |
|---|---|---|
| Pharmacokinetic Results of Atazanavir (ATV): Treatment A: ATV/Low-Dose Ritonavir (Rtv) 300/100 mg (Results for AUC24hr) | 60030 ± 39690 | 55070 ± 21860 |
The table below shows pharmacokinetic (PK) results of atazanavir (ATV) when administered as ATV/ritonavir (rtv) 300/100 mg pretreatment (Reference) and when administered as ATV/rtv 400/100 mg at Week 2 after treatment (Test). Results are expressed as the predose plasma concentration (C0h), minimum plasma concentration (Cmin), maximum plasma concentration (Cmax), and area under the plasma concentration-time curve from time of intake to 24 hours after dosing (AUC24hr).
| ng/ml | ATV/Rtv 300/100 mg (Reference) | ATV/Rtv 400/100 mg (Test) |
|---|---|---|
| C0h, ng/ml (Reference, n=22; Test, n=20) | 1898 ± 2298 | 1545 ± 1296 |
| Cmin, ng/ml (Reference, n=21;Test, n=18) | 1671 ± 2310 | 1107 ± 866.8 |
| Cmax, ng/ml (Reference, n=22; Test, n=20) | 6419 ± 2853 | 6950 ± 2693 |
The table below shows pharmacokinetic (PK) results of atazanavir (ATV) when administered as ATV/ritonavir (rtv) 300/100 mg pretreatment (Reference) and when administered as ATV/rtv 400/100 mg at Week 2 after treatment (Test). Results are expressed as the area under the plasma concentration-time curve from time of intake to 24 hours after dosing (AUC24hr).
| ng.h/mL | ATV/Rtv 300/100 mg (Reference) | ATV/Rtv 300/100 mg (Test) |
|---|---|---|
| Pharmacokinetic Results of Atazanavir (ATV): Treatment B: ATV/Low-Dose Ritonavir (Rtv) 400/100 mg (Results for AUC24hr) | 74210 ± 55480 | 72220 ± 34600 |
The table below shows the pharmacokinetic (PK) results of low-dose ritonavir (rtv) when administered as atazanavir (ATV)/rtv 300/100 mg pretreatment (Reference) and at Week 2 after treatment (Test). Results are expressed as the predose plasma concentration (C0h), minimum plasma concentration (Cmin), and maximum plasma concentration (Cmax).
| ng/ml | ATV/Rtv 300/100 mg (Reference) | ATV/Rtv 300/100 mg (Test) |
|---|---|---|
| C0h, ng/ml (Reference, n=21; Test, n=19) | 143.4 ± 269.8 | 102.5 ± 157.2 |
| Cmin, ng/ml (Reference, n=20; Test, n=18) | 60.42 ± 73.17 | 43.97 ± 36.29 |
| Cmax, ng/ml (Reference, n=20; Test, n=19) | 1834 ± 1009 | 1740 ± 1149 |
The table below shows the pharmacokinetic (PK) results of low-dose ritonavir (rtv) when administered as atazanavir (ATV)/rtv 300/100 mg pretreatment (Reference) and at Week 2 after treatment (Test). Results are expressed as the area under the plasma concentration-time curve from time of intake to 24 hours after dosing (AUC24hr).
| ng.h/ml | ATV/Rtv 300/100 mg (Reference) | ATV/Rtv 300/100 mg (Test) |
|---|---|---|
| Pharmacokinetic Results of Low-Dose Ritonavir (Rtv): Treatment A: Atazanavir (ATV)/Rtv 300/100 mg (Results for AUC24hr) | 12560 ± 6643 | 11120 ± 6658 |
The table below shows pharmacokinetic (PK) results of low-dose ritonavir (rtv) when administered as atazanavir (ATV)/ritonavir (rtv) 300/100 mg pretreatment (Reference) and when administered as ATV/rtv 400/100 mg at Week 2 after treatment (Test). Results are expressed as the predose plasma concentration (C0h), minimum plasma concentration (Cmin), maximum plasma concentration (Cmax), and area under the plasma concentration-time curve from time of intake to 24 hours after dosing (AUC24hr).
| ng/ml | ATV/Rtv 300/100 mg (Reference) | ATV/Rtv 400/100 mg (Test) |
|---|---|---|
| C0h, ng/ml (Reference, n=22; Test, n=20) | 109.2 ± 94.50 | 163.4 ± 240.2 |
| Cmin, ng/ml | 64.70 ± 51.80 | 75.68 ± 69.98 |
| Cmax, ng/ml (Reference, n=22) | 1882 ± 1026 | 1847 ± 859.9 |
The table below shows pharmacokinetic (PK) results of low-dose ritonavir (rtv) when administered as atazanavir (ATV)/ritonavir (rtv) 300/100 mg pretreatment (Reference) and when administered as ATV/rtv 400/100 mg at Week 2 after treatment (Test). Results are expressed as the area under the plasma concentration-time curve from time of intake to 24 hours after dosing (AUC24hr).
| ng.h/ml | ATV/Rtv 300/100 mg (Reference) | ATV/Rtv 300/100 mg (Test) |
|---|---|---|
| Pharmacokinetic Results of Low-Dose Ritonavir (Rtv): Treatment B: Atazanavir (ATV)/Rtv 400/100 mg (Results for AUC24hr) | 13880 ± 8198 | 13660 ± 6778 |
The table below shows pharmacokinetic (PK) results of ETR in the current study expressed as the predose plasma concentration (C0h), minimum plasma concentration (Cmin) and maximum plasma concentration (Cmax).
| ng/ml | ATV/Rtv 300/100 mg (Treatment A) | ATV/Rtv 400/100 mg (Treatment B) |
|---|---|---|
| C0h (Treatment B, n=19) | 422.2 ± 327.9 | 316.6 ± 215.4 |
| Cmin (Treatment A, n=16; Treatment B, n=18) | 425.1 ± 328.1 | 286.5 ± 198.0 |
| Cmax (Treatment A, n=18; Treatment B, n=18) | 773.0 ± 360.5 | 628.7 ± 294.0 |
The table below shows pharmacokinetic (PK) results of ETR in the current study expressed as the area under the plasma concentration-time curve from time of intake to 12 hours after dosing (AUC12hr).
| ng.h/mL | ATV/Rtv 300/100 mg (Treatment A) | ATV/Rtv 400/100 mg (Treatment B) |
|---|---|---|
| Pharmacokinetic Results of Etravirine (ETR) (Results for AUC12hr) | 7629 ± 4213 | 5171 ± 2695 |
The table below shows the percentage of participants wih undetectable plasma viral load (VL) values (\<50 copies/mL) at Week 48 using the Non-Completing = Failure (NC=F) imputation method (ie, participants who discontinued early were counted as nonresponders by having their VL values after discontinuation imputed with their baseline value, thus resulting in a 0 change).
| Percentage of Participants | ATV/Rtv 300/100 mg (Treatment A) | ATV/Rtv 400/100 mg (Treatment B) |
|---|---|---|
| Percentage of Participants With Undetectable Plasma Viral Load (VL) Values (<50 Copies/mL) at Week 48 | 50.0 (28.2 to 71.8) | 45.5 (45.5 to 67.8) |
The table below shows the mean change from prebaseline over time in CD4+ cell count using the Non-Completing = Failure (NC=F) imputation method.
| CD4+ cell count | ATV/Rtv 300/100 mg (Treatment A) | ATV/Rtv 400/100 mg (Treatment B) |
|---|---|---|
| Baseline | 16 ± 11.8 | 8 ± 18 |
| Week 4 | 55 ± 15.4 | 46 ± 27.4 |
| Week 12 | 31 ± 15.0 | 72 ± 23.5 |
| Week 24 | 54 ± 22.0 | 83 ± 23.2 |
| Week 48 | 105 ± 31.1 | 132 ± 32.6 |
The table below shows the percentage of participants per time point with a virologic response defined as having a plasma viral load (VL) \<50 copies/mL, and with plasma VL \<400 copies/mL using the Non-Completing = Failure (NC=F) imputation method (ie, participants who discontinued early were counted as nonresponders by having their VL values after discontinuation imputed with their Baseline value, thus resulting in a 0 change).
| Percentage of Participants | ATV/Rtv 300/100 mg (Treatment A) | ATV/Rtv 400/100 mg (Treatment B) |
|---|---|---|
| <50 copies/mL, Baseline | 9.1 | 9.1 |
| <50 copies/mL, Week 4 | 31.8 | 36.4 |
| <50 copies/mL, Week 12 | 59.1 | 59.1 |
| <50 copies/mL, Week 24 | 63.6 | 63.6 |
| <50 copies/mL, Week 48 | 50.0 | 45.5 |
| <400 copies/mL, Baseline | 40.9 | 40.9 |
| <400 copies/mL, Week 4 | 77.3 | 77.3 |
| <400 copies/mL, Week 12 | 68.2 | 81.8 |
| <400 copies/mL, Week 24 | 72.7 | 72.7 |
| <400 copies/mL, Week 48 | 50.0 | 59.1 |
The table below shows the percentage of participants with a virologic response defined as a viral load \<50 Copies/mL and \<400 Copies/mL per time point calculated using the time to loss of virologic response (TLOVR) imputation method.
| Percentage of Particpants | ATV/Rtv 300/100 mg (Treatment A) | ATV/Rtv 400/100 mg (Treatment A) |
|---|---|---|
| <50 copies/mL, Baseline | 9.1 | 4.5 |
| <50 copies/mL, Week 4 | 31.8 | 36.4 |
| <50 copies/mL, Week 12 | 59.1 | 54.5 |
| <50 copies/mL, Week 24 | 63.6 | 59.1 |
| <50 copies/mL, Week 48 | 45.5 | 50.0 |
| <400 copies/mL, Baseline | 36.4 | 40.9 |
| <400 copies/mL, Week 4 | 77.3 | 77.3 |
| <400 copies/mL, Week 12 | 68.2 | 86.4 |
| <400 copies/mL, Week 24 | 68.2 | 68.2 |
| <400 copies/mL, Week 48 | 59.1 | 54.5 |
The table below provides the results from the snapshot analysis method that includes the percentage of participants with virologic response (\<50 copies/mL), the percentage of participants who were virologic failures (VF) (\>50 copies/mL, discontinued prior to time X for reasons of VF or for other reasons, except for VF or adverse event, with a last viral load \>50 copies/mL), and the percentage of participants with no viral load (VL) data available at Week 48.
| Percentage of Participants | ATV/Rtv 300/100 mg (Treatment A) | ATV/Rtv 400/100 mg (Treatment B) |
|---|---|---|
| Virologic Response | 50.0 | 45.5 |
| Virologic Failure | 31.8 | 36.4 |
| No VL Data Available | 18.2 | 18.2 |
The table below shows the mean change from prebaseline over time in log10 (Copies/mL) plasma viral load using the Non-Completing = Failure (NC=F) imputation method.
| log10 (Copies/mL) | ATV/Rtv 300/100 mg (Treatment A) | ATV/Rtv 400/100 mg (Treatment B) |
|---|---|---|
| Baseline | -1.4 ± 0.14 | -1.4 ± 0.18 |
| Week 4 | -1.9 ± 0.18 | -1.8 ± 0.15 |
| Week 12 | -1.7 ± 0.26 | -2.0 ± 0.23 |
| Week 24 | -1.8 ± 0.24 | -1.8 ± 0.27 |
| Week 48 | -1.4 ± 0.24 | -1.4 ± 0.29 |
The table below provides the time in days it took participants to reach a confirmed virologic response defined as a plasma viral load (VL) \<50 copies/mL, and plasma VL \<400 copies/mL analyzed according to the Time to Loss of Virologic Response (TLOVR) imputation method.
| Days | ATV/Rtv 300/100 mg (Treatment A) | ATV/Rtv 400/100 mg (Treatment B) |
|---|---|---|
| Plasma VL < 50 copies/mL | 71.0 ± 10.87 | 76.0 ± 9.95 |
| Plasma VL < 400 copies/mL | 28.0 ± 5.02 | 28.0 ± 6.47 |
The table below shows the number of days to virologic failure defined as a plasma viral load (VL) \> 50 copies/mL for participants who had been virologic responders (ie, having a plasma VL \<50, and \<400 copies/mL according to the time to loss of virologic response \[TLOVR\] imputation method). Time to virologic failure was the time to subsequent loss of virologic response, and the time was calculated from Prebaseline (Week -2). Participants who never achieved a virologic response were defined as nonresponders and counted as virologic failures on Day 1.
| Days | ATV/Rtv 300/100 mg (Treatment A) | ATV/Rtv 400/100 mg (Treatment B) |
|---|---|---|
| Virologic Responders (Plasma VL < 50 copies/mL) | 318.0 ± 31.90 | NA ± 22.46 |
| Virologic Responders (Plasma VL < 400 copies/mL) | NA ± 28.92 | NA ± 17.28 |
Collected over Up to a maximum of 56 weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| ATV/Rtv 300/100 mg (Treatment A) | — | 4/25 (16%) | 21/25 (84%) |
| ATV/Rtv 400/100 mg (Treatment B) | — | 2/25 (8%) | 15/25 (60%) |
| Event | ATV/Rtv 300/100 mg (Treatment A) | ATV/Rtv 400/100 mg (Treatment B) |
|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 1/25 | 0/25 |
| GastroenteritisInfections and infestations | 1/25 | 0/25 |
| Meningitis asepticInfections and infestations | 1/25 | 0/25 |
| PneumoniaInfections and infestations | 1/25 | 1/25 |
| SinusitisInfections and infestations | 1/25 | 0/25 |
| Bowen's diseaseNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/25 | 1/25 |
| Metastatic malignant melanomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/25 | 0/25 |
| HeadacheNervous system disorders | 0/25 | 1/25 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 1/25 | 0/25 |
| Accidental overdoseInjury, poisoning and procedural complications | 1/25 | 0/25 |
| Event | ATV/Rtv 300/100 mg (Treatment A) | ATV/Rtv 400/100 mg (Treatment B) |
|---|---|---|
| CoughRespiratory, thoracic and mediastinal disorders | 5/25 | 4/25 |
| NauseaGastrointestinal disorders | 4/25 | 1/25 |
| HyperbilirubinaemiaHepatobiliary disorders | 3/25 | 0/25 |
| InfluenzaInfections and infestations | 2/25 | 3/25 |
| Upper respiratory tract infectionInfections and infestations | 2/25 | 3/25 |
| Blood bilirubin increasedInvestigations | 3/25 | 2/25 |
| HeadacheNervous system disorders | 3/25 | 3/25 |
| RashSkin and subcutaneous tissue disorders | 3/25 | 1/25 |
| Abdominal painGastrointestinal disorders | 0/25 | 2/25 |
| DiarrhoeaGastrointestinal disorders | 2/25 | 2/25 |
| Age, Categorical(Participants) | ATV/Rtv 300/100 mg (Treatment A) | ATV/Rtv 400/100 mg (Treatment B) | Total |
|---|---|---|---|
| <=18 years | 0 | 1 | 1 |
| Between 18 and 65 years | 25 | 24 | 49 |
| >=65 years | 0 | 0 | 0 |
| Age Continuous(years) | ATV/Rtv 300/100 mg (Treatment A) | ATV/Rtv 400/100 mg (Treatment B) | Total |
|---|---|---|---|
| Mean | 41.2 ± 10.44 | 39.8 ± 9.37 | 40.5 ± 9.85 |
| Sex: Female, Male(Participants) | ATV/Rtv 300/100 mg (Treatment A) | ATV/Rtv 400/100 mg (Treatment B) | Total |
|---|---|---|---|
| Female | 12 | 13 | 25 |
| Male | 13 | 12 | 25 |
This study is completed, as verified in Sep 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Janssen R&D Ireland